Stem Cell Treatment for Erectile Dysfunction

Stem Cell Treatment for Erectile Dysfunction

STEM CELL TREATMENT ERECTILE DYSFUNCTION

Stem Cell Treatment for Erectile Dysfunction

  • Erectile Dysfunction is a sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance.

  • Stem Cell Treatmentst aims to effect the Calcium-sensitive potassium channel and therefore help increase the flow of blood into the Corpus.

STEM CELL TREATMENT ERECTILE DYSFUNCTIONA penile erection is the hydraulic effect of blood entering and being retained in sponge-like bodies within the penis. The process is often initiated as a result of sexual arousal, when signals are transmitted from the brain to nerves in the penis. Erectile dysfunction is indicated when an erection is difficult to produce. There are various circulatory causes, including alteration of the voltage-gated potassium channel, as in arsenic poisoning from drinking water.

The most important organic causes are cardiovascular disease and diabetes, neurological problems (for example, trauma from prostatectomy surgery), hormonal insufficiencies (hypogonadism) and drug side effects.

Psychological impotence is where erection or penetration fails due to thoughts or feelings (psychological reasons) rather than physical impossibility; this is somewhat less frequent but often can be helped. Notably in psychological impotence, there is a strong response to placebo treatment. Erectile dysfunction, tied closely as it is about ideas of physical well being, can have severe psychological consequences.

Stem Cell Treatment for Erectile Dysfunction

NIH Streaming Database:

Related Articles The feasibility of the CD271+ and CD271- mesenchymal stromal cell enrichment toward nucleus pulposus-like cells. Folia Histochem Cytobiol. 2017 Sep 19;: Authors: Jezierska-Wozniak K, Barczewska M, Habich A, Wojtacha P, Badowska W, Maksymowicz W, Wojtkiewicz J Abstract INTRODUCTION: Factors promoting nerve cell ingrowth are considered responsible for chronic back pain resulting from the intervertebral disc degeneration (IDD). One of the recent exploratory IDD treatments is stem cell transplantation therapy. The CD271 (low-affinity nerve growth factor receptor) has been identified as a marker of the most homogeneous mesenchymal stem cell (MSC) subset. It is capable of promoting differentiation along adipogenic, osteogenic and chondrogenic lineages and producing significantly higher levels of cytokines as compared to the total population of plastic adherence-mesenchymal stem cells (PA-MSCs). We investigated the ability of CD271+ MSCs to differentiate into chondrocyte-like cells of the nucleus pulposus (NP) of intervertebral disc. We also examined CD271- MSCs, using PA-MSCs as a control cell population. MATERIAL AND METHODS: Bone marrow derived PA-MSCs and its two subsets, CD271- MSCs and CD271+ MSCs, were seeded in collagen scaffolds. After two weeks of growth in NP-differentiation medium, RNA was isolated from cells-scaffold constructs and was analyzed by q-PCR for expression of NP markers. Glycosaminoglycans (GAG) were analyzed biochemically directly in cells-scaffold constructs. RESULTS: Expression of NP markers - extracellular matrix components such as aggrecan, collagen type II (COL II) and glycosaminoglycans on both RNA and the protein levels - was significantly higher in CD271- MSCs compared to the CD271+ MSCs and PA-MSCs cell populations. CONCLUSIONS: CD271- MSCs may be superior candidates for NP restorative treatment compared to CD271+ MSCs and PA-MSCs due to their ability of expressing NP-supporting extracellular matrix components at levels higher than the other two studied MSC subsets. PMID: 28925497 [PubMed - as supplied by publisher]
Read more...

Quick Contact Form